What is the price of the domestic targeted drug sotoraxib (AMG510)?

As of now, the domestically produced targeted drug sotoracib (AMG510) has not yet been officially launched in China, so the exact information about its price is not known. The development of sotoracib is a tumor treatment drug targeting KRAS G12C mutations. Its development is of great significance because KRAS mutations have long been considered one of the main causes of incurable cancers.

The R&D and marketing of domestically produced sotoracib involves a series of research, clinical trials and approval processes. Typically, this process requires rigorous review and approval by drug regulatory agencies to ensure the safety, effectiveness and quality of the drug. Therefore, the price of domestically produced sotoracib will be affected by a variety of factors, including research and development costs, production costs, market competition, government policies, etc.

In China, the price of targeted drugs is usually relatively high, which is partly due to high research and development costs, complex technical requirements, and relatively small production scale. At the same time, due to the fierce competition in the domestic pharmaceutical market, once sotorasibu is officially launched, it may be affected by competition from other similar drugs, thus affecting its price to a certain extent.

However, generic drugs are often more affordable than brand-name drugs. If domestically produced sotorasibu can be successfully marketed, it may provide a more affordable option for patients in need of this drug. This will also help improve access to medicines, allowing more patients to receive necessary treatments.

Before waiting for the domestically produced sotorasibu to be launched, patients can consider other ways to obtain the drug, such as participating in clinical trials, purchasing overseas original drugs or generic drugs, etc. However, it should be noted that no matter how you obtain drugs, you should do so under the guidance of a doctor, and ensure that the source of the drugs is legal and reliable to ensure the safety and effectiveness of the treatment.

To sum up, the price of domestically produced sotorasibu has not yet been determined, but it is expected that it will provide more economical and affordable treatment options for domestic patients and bring new hope and opportunities to tumor patients.